本文選題：成人生長激素缺乏癥 + 生長激素替代治療　； 參考：《浙江大學(xué)》2015年碩士論文

【摘要】：目的：成人生長激素缺乏癥可致機(jī)體組分改變、糖脂代謝紊亂、骨代謝異常、心血管疾病風(fēng)險(xiǎn)增加等,生長激素替代治療可有效改善以上情況,但生長激素替代治療的安全性目前仍備受爭議,尤其在腫瘤發(fā)生風(fēng)險(xiǎn)方面。目前已知國內(nèi)外發(fā)表的文章中尚未有關(guān)于這方面的統(tǒng)計(jì),本文通過對國內(nèi)外有關(guān)生長激素替代治療對成人生長激素缺乏癥患者腫瘤發(fā)生風(fēng)險(xiǎn)相關(guān)研究進(jìn)行定量統(tǒng)計(jì)分析,旨在探討生長激素替代治療是否增加成人生長激素缺乏癥患者腫瘤發(fā)生風(fēng)險(xiǎn)。 方法：應(yīng)用Cochrane系統(tǒng)評價(jià)方法,對PUBMED、Web of Science、Ovid、Cochrane、中國生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫(CBM)、相關(guān)期刊論文(CNKI)、萬方數(shù)據(jù)庫自建庫以來至2015年3月所有文獻(xiàn)進(jìn)行檢索。文獻(xiàn)語種為中文和英文。查找符合納入標(biāo)準(zhǔn)的隨機(jī)對照試驗(yàn)和隊(duì)列研究,對其進(jìn)行質(zhì)量評價(jià),使用Revman5.0軟件對提取的相關(guān)數(shù)據(jù)進(jìn)行meta分析。 結(jié)果：本文共納入8個(gè)隊(duì)列研究,總共11106名AGHD患者,平均隨訪時(shí)間為7.4年。結(jié)果顯示GH治療組的AGHD患者腫瘤發(fā)生的風(fēng)險(xiǎn)較非GH治療組無增加。亞組分析顯示回顧性及前瞻性隊(duì)列研究中GH治療組與非GH治療組相比較腫瘤發(fā)生風(fēng)險(xiǎn)無增加。樣本量≤000例和樣本量1000例的研究中GH治療組與非GH治療組相比較腫瘤發(fā)生風(fēng)險(xiǎn)無增加。 結(jié)論：本meta分析結(jié)果顯示,AGHD患者使用GH替代治療與未使用GH替代治療相比,腫瘤發(fā)生風(fēng)險(xiǎn)未增加。
[Abstract]:Objective: adult growth hormone deficiency can cause changes in body composition, disorder of glucose and lipid metabolism, abnormal bone metabolism, increased risk of cardiovascular disease, etc. Growth hormone replacement therapy can effectively improve these conditions.However, the safety of growth hormone replacement therapy is still controversial, especially in cancer risk.At present, there are no statistics on this aspect in the articles published at home and abroad. This paper makes a quantitative statistical analysis on the risk of tumor occurrence in adult growth hormone deficiency patients by using the growth hormone replacement therapy at home and abroad.Objective to investigate whether growth hormone replacement therapy increases the risk of tumor in adults with growth hormone deficiency.Methods: using the method of Cochrane system evaluation, all the literatures of PUBMEDU Web of Science Ovidor Cochrane, China Biomedical Literature Database, China Journal Full-text Database and Wanfang Database were searched from time to March 2015.The languages of the literature are Chinese and English.Random controlled trials and cohort studies that meet the inclusion criteria were searched for quality evaluation and meta analysis of the extracted data was carried out using Revman5.0 software.Results: a total of 11106 AGHD patients were enrolled in 8 cohort studies with an average follow-up time of 7.4 years.The results showed that there was no increase in tumor risk in GH group compared with non-GH group.Subgroup analysis showed that there was no increase in tumor risk in the GH group compared with the non-GH group in a retrospective and prospective cohort study.In the study of sample size 鈮，

本文編號：1761641